URGN EBITDA Growth
Urogen Pharma Ltd · EBITDA Growth
URGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported45.48%period ending
URGN TTM EBITDA YoY % (107.88% → 45.48%)
Year-over-year change
High-resolution chart · PNG
URGN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 45.4849% | |
| -5.772% | |
| -43.7884% | |
| -85.0208% | |
| -76.1727% | |
| -73.0139% | |
| -43.6115% | |
| 8.7727% | |
| 21.1428% | |
| 30.3353% | |
| 28.5447% | |
| 4.7159% | |
| 2.165% | |
| 10.9657% | |
| 8.3871% | |
| 19.2233% | |
| 11.0657% | |
| 9.1524% | |
| 18.9912% | |
| 20.8874% | |
| 18.5839% | |
| 8.7765% | |
| -14.5441% | |
| -45.5686% | |
| -43.5837% | |
| -43.5747% | |
| -40.9099% | |
| -48.4423% | |
| -115.879% | |
| -189.1197% | |
| -288.7656% | |
| -1,549.9654% | |
| -2,853.0112% | |
| -2,847.9147% | |
| -2,052.819% | |
| 121.8051% | |
| 90.9974% | |
| 107.8805% |